Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
2024-11-28
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain TAIPEI – November 28, 2024 – Taiwan-based Formosa Pharmaceuticals
